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Pulse Glucometry: A New Approach for Non-invasive Blood 
Glucose Measurement Using Instantaneous Differential Near 
Infrared Spectrophotometry. 
1. Introduction 
In vivo spectrophotometric analysis attracts at-
tention due to its potential for allowing safe, 
convenient, non-invasive biochemical measure-
ment. Whilst the prospects for general bio-
chemical analysis are often proposed and dis-
cussed much of the attention has actually been 
focused on blood glucose (BGL) measurement 
because reliable BGL assessment is a vital part of 
self-care by the increasing number of diabetic 
patients worldwide. Optical methods apart, for 
more than four decades improved BGL moni-
toring based on other principles has also been 
sought, in particular to eliminate the need for the 
frequent, often painful, finger-pricking and blood 
analysis which, even today, remains the most 
widely used method. Over this period several 
potential alternatives have emerged, including 
invasive implantable micro-sensors [ , ]1 2 , the 
minimally invasive procedure of skin micropo-
ration using a laser or miniaturized lancets [ ]3 , as 
well as transdermal measurement based on ex-
traction of interstitial fluids through the skin us-
ing iontophoresis [ , ]4 5  or sonophoresis [ ]6 . The 
subject has been reviewed by several authors; see, 
for example ref. [7]. 
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Truly non-invasive BGL measurement has been 
sought for many years and optical methods in 
general have appeared to offer very strong pros-
pects for achieving this [ , , ]8 9 10 . These optical 
methods have included the measurement of the 
rotation of optical polarisation in the aqueous 
humor of the eye [ , ]11 12  or a colorimetric contact 
lens measuring in tear film [ ]13  or the use of near 
infrared spectroscopy, NIRS, in tissues such as 
the finger or the lip [ , ]14 15 . Raman spectroscopy 
has also been investigated for this purpose [ ]16 . 
Most of these methods have been explored 
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widely but to date, apparently, none has provided 
sufficiently precise and accurate measurements 
for reliable clinical use [14]. The obstacles to 
success with in vivo NIRS for BGL measurement 
are, on the one hand, the very small in vivo 
spectral signal of glucose and, on the other hand 
the combination of interference from other ab-
sorbing species, multiple scatter in skin, muscle 
and bone, and the strong absorption bands of 
water [9, , ]17 18 . Indeed, the optical absorption 
spectrum of water effectively masks glucose 
absorption bands as determined with conven-
tional NIR spectrophotometers. There are clearly 
substantial difficulties in using spectroscopic 
techniques for non-invasive measurement of 
glucose not least of which is that often methods 
used for assessing the validity of a given tech-
nique are not fully described by authors, as re-
ported by Arnold and Small [18]. 
We have recently designed a novel NIRS tech-
nique [ ]19 , which we term Pulse Glucometry. This 
method has been designed to minimise, or re-
move, influences of many of the confounding 
factors by collecting optical data from pulsatile 
blood volume changes in tissue. There is a sub-
stantial literature describing uses of pho-
toplethysmography for monitoring several 
physiological variables such as blood volume and 
flow, oxygen saturation and blood constituents 
such as glucose [15, , , , ]20 21 22 23 .  The invention of 
pulse oximetry by Aoyagi [ , ]24 25  has had the most 
important clinical impact of all of these devel-
opments to date. The essence of this technique is 
to make photoplethysmographic measurements 
of arterial blood volume pulsations, typically at 
two wavelengths, one in the red and the other in 
the infra-red parts of the spectrum, then to derive 
simple ratios of these measurements to determine 
the relative proportions of the two most signifi-
cant chromophores oxy- and deoxy-haemoglobin. 
The patent literature reveals many attempts to use 
spectrophotometric techniques to measure blood 
glucose and a method based on two-wavelength 
analysis of the arterial pulse signal has been 
proposed [ ]26 . The invention by these authors 
claims to use one wavelength which is “glucose 
sensitive” and a second wavelength which is 
“glucose insensitive” then, as with pulse oxi-
metry, to use ratios of pulsatile-to-continuous 
components of the photoplethysmogram at each 
wavelength to derive an estimate of glucose 
concentration. Although this invention was clas-
sified as a granted patent in 1992 no instrument 
has yet been made available for use. In fact, this 
situation is characteristic of the non-invasive 
glucose monitoring field, where numerous 
granted patents exist and no clinically accepted 
instrument is yet available.  
This paper represents our first description of 
Pulse Glucometry together with preliminary in 
vivo results. There is clearly much more research 
to be done before all technical and clinical as-
pects of our method have been fully investigated. 
For example, we must thoroughly investigate 
further the performance of the chemometric 
methods of analysis which we have used, since 
there are many possible shortcomings as pointed 
out by others [15, 18]. Nevertheless, we feel that the 
results obtained to date are sufficiently encour-
aging to report the method as one worth serious 
consideration in this field of non-invasive blood 
glucose monitoring. 
Basic Principle of the Measurement 
The method described here utilises spectropho-
tometric analysis in a tissue segment, such as a 
finger. Glucose exhibits several absorption bands 
between 0.7 µm and 2.5 µm and within this range 
it is of importance that there are broad and strong 
water absorption bands at 1.45 µm and 1.92 µm 
[ ]27 .  In order to avoid these bands it appears 
theoretically possible to use the combination re-
gion (2.0 µm to 2.5 µm), the first overtone region 
(1.54 µm to 1.82 µm) and the near infra-red re-
gion (0.7 µm to 1.33 µm). Glucose exhibits three 
absorption bands in each of these regions: 2.10 
µm, 2.27 µm and 2.32 µm in the combination 
region; 1.73 µm, 1.69 µm and 1.61 µm in the first 
overtone region; 0.76 µm, 0.92 µm and 1.00 µm 
in the near infra-red region. Of these glucose 
absorption bands the latter in the near infra-red 
region are particularly weak [14, 15]. To recover the 
glucose information in tissue having high water 
content multivariate analysis covering a suitable 
region of the optical spectrum must be used. The 
essence of our new approach is to utilise a blood 
volume change in a tissue segment under optical 
interrogation, such as a finger, and then, with a 
subtraction process, to derive changes in optical 
density (OD) in order to remove the influences of 
basal interfering elements.  
We assume a simplified model of the tissue under 
interrogation, as shown in Fig 1, (left panel). This 
optical model comprises of three compartments: 
arterial; venous; and bloodless tissue. The optical 
interrogation of the tissue is carried out with a 
broad-spectrum light source having incident ra-
diation intensity 0  with the wavelength λ. 
Following absorption and scattering in each 
compartment we have transmitted radiation in-
tensity, λ . The arterial blood volume changes in 
a pulsatile way throughout the cardiac cycle, 
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JouFig. 1: Basic principle of non-invasive measurement of blood glucose concentration (BGL)
using instantaneous differential near-infrared spectrophotometry. Optical model of the bio-
logical tissue (fingertip) is shown in the inset in the left panel. See text for explanation.  reby producing small changes in the trans-
tted intensity, . If the transmitted inten λI∆
y, λ ,I  is detected periodically at time intervals 
during the cardiac cycle, we obtain a time se-
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This subtraction has the effect of removing the 
venous and the tissue contributions to yield only 
the change in intensity due to the pulsating arte-
rial blood compartment. If now the transmitted 
radiation is spectrally resolved into its component 
individual wavelengths it will be possible to re-
cover a family of time-series, each member dis-
playing the pulsatile intensity change present at 
one wavelength, as shown in Fig. 1 (upper panel). 
In order to implement this general principle in 
practice we use the peak-to-peak magnitude of 
each cardiac-related pulse. The magnitudes of the 
cardiac-related pulsatile intensity components at 
wavelengths λ1,λ2,....λn  are given as 
nλλλ III ∆∆∆ ,..., 21 . Based on equation (5) we 
can then convert these into changes in optical 
density 
n
ODODOD λλλ ∆∆∆ ,..., 21 . 
These data can also be viewed as spectra, for 
example over a near infra-red range, with 
λOD∆  plotted against wavelength, λ. If such 
spectra are derived at different levels of blood 
glucose concentration, BGLi, we will obtain a 
family of spectra, as is illustrated schematically 
in Fig. 1(lower part), which may then be used for 
a multivariate analysis. As is common in 
multi-component spectrophotometric analysis we 
use a Partial Least Squares (PLS) calibration 
model in order to obtain predictions of BGL [8, 9, 10, 
15, 18, 23, 27, ]28 . The PLS model is first constructed 
by measuring blood glucose directly together 
with non-invasive optical measurements in a 
representative population. Then, for a given 
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subject, spectra of λ  vs λ for the unknown 
BGL values derived from in vivo measurements 
are compared with the PLS-derived calibration 
model and predicted BGL values thereby calcu-
lated. 
OD∆
Materials & Methods 
In order to obtain an instantaneous spectrum of 
the transmitted radiation through the tissue, we 
have developed a new, fast, spectrophotometer. 
Fig. 2 shows a block diagram of this system. It 
comprises of a light source (halogen lamp: 
maximum power; 150 W), an optical fibre bundle 
of 10 mm diameter for the incident radiation and 
a single fibre of 1.2 mm diameter for receiving 
the transmitted radiation, a spectrometer (poly-
chromator: M25-TP; Bunkoh-Keiki Co. Ltd., 
Japan), a linear, liquid nitrogen cooled (-50－
-100 ), InGaAs photodiode-array 
(multi-photo-detector: OMA V: 512-1.7(LN); 
Princeton Instruments Co., USA), and a conven-
tional PC with an appropriate interface. The 
spectrometer covers an effective wavelength 
range from 900 nm to 1700 nm with a resolution 
of better than 8 nm, and it has a maximum spec-
tral rate of 1800 spectra/s with 1 MHz digitization 
(16 bits), and a minimum exposure time of 20 µs. 
A key component of our instrument is the 
multi-photo-detector. The model we used has a 
particularly high specification, and in terms of 
dark current, linearity and stability it is at pre-
sent probably one of the best commercially 
available worldwide (see detailed information: 
http://architect.wwwcomm.com/Uploads/Princet
on/Documents/Datasheets/omav_512-17ln.pdf).  
The spectral noise of the instrument was evalu-
ated both in vitro and in vivo. Firstly, for the in 
vitro assessment, we recorded sequential trans-
mission spectra from a 1.0 mm cuvette contain-
ing water and then calculated the difference be-
tween sequential pairs of spectra. This indicated 
a spectral noise value of 20 µAU over the cho-
sen operating wavelength range from 900 to 
1700 nm. We then inserted a neutral density fil-
ter having an attenuation of 2.0 AU into the op-
tical path, in addition to the 1.0 mm cuvette 
containing water, and once again repeated the 
acquisition of sequential spectra together with 
calculation of the difference spectra. This gave 
us a spectral noise value of around 30 µAU over 
the same wavelength range. Secondly, we ac-
quired sequential transmission spectra from a 
fingertip whilst an occlusion cuff was applied 
around the basal phalanx of the finger to halt 
blood circulation for a period of about 5 s. Once 
again this allowed us to derive difference spectra 
from the sequential pairs of transmission spectra 
to determine the spectral noise value, but it also 
enabled us to assess stability and repeatability 
over the 5-s period. The spectral noise level was 
found to be around 30 µAU over the wavelength 
range of 900 to 1700 nm. For about 50 sequen-
tial measurements made over the 5-s period, 
with an exposure time of 10 ms in the 
multi-photo-detector, we found a spectral noise 
variation of around 0.5 %. 
Fig. 2: Block diagram of the high-speed near infrared spectrophotometric system. See text for 
details. 
In order to carry out in vivo measurements glu-
cose tolerance tests were carried out in 27 healthy 
volunteers, after obtaining informed consent 
(20-43 years old; 24 males and 3 females). The 
subjects were asked to abstain from food and 
alcohol from 9 pm on the previous day until the 
end of the experiment on the next morning. The 
experiment began at 9 am in a tempera-
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ture-controlled room held at 25 ºC. During the 
experiment the subjects were requested to sit 
quietly in a chair to undergo the test. Radiation 
intensity measurements were made in the left 
index fingertip at regular intervals before and 
after oral administration of glucose solution 
(75g/225ml: Trelan-G75; Shimizu Seiyaku, Co. 
Ltd., Japan) for a study period of 120 min. During 
the optical measurement the subject’s left hand 
was held horizontally at heart level. In some 
subjects the interval between optical measure-
ments was 10 minutes and in the remainder the 
interval was 5 minutes. Immediately after each 
optical measurement blood samples (about 3 ml) 
were collected from the cephalic vein of the left 
forearm. The sampled blood was immediately 
analyzed by an automatic blood analyzer 
(DRI-CHEM 7000; Fujifilm Medical Co. Ltd., 
Japan) to obtain the reference BGL value 
(measured BGL). The analyzer uses a colorimet-
ric principle based on glucose oxidase contained 
within single-use multi-layer film elements. 
Quality control data accompanying each film 
element are entered into the analyzer thereby 
ensuring automatic updating of calibration with 
every use. 
For the optical intensity measurements, the fin-
gertip was placed carefully in an adjustable space 
between the ends of the transmitting and receiv-
ing fibres so as to contact softly with the skin (see 
the inset in Fig. 3). The intensity measurements 
were made for about 20-30 s (about 20-30 cardiac 
pulses), spectra being gathered at a rate of 100 s-1. 
These conditions could achieve a measurement of 
the pulse component signal ( λ ) superimposed 
on the intensity ( λ ) with a signal-to-noise ratio 
(SNR) of more than 25 dB over the wavelength 
range from 900 to 1400 nm and approxi-
mately 22 dB from 1400 to 1700nm. In the 
calculation of the change in absorbance 
( λ ), however, since we have con-
firmed this SNR to be more than 20 dB 
above 1400 nm, we believe that the calcu-
lated λ∆  is sufficiently accurate 
within the range from 900 to 1700 nm. In 
order to gain an impression of the instru-
ment noise level we can see from the 
spectra shown in Fig 5 that there is noise 
just discernable on the tracing, especially 





In each subject during the 120-min study 
period 13 (10-min interval) or 25 (5-min 
interval) sets of the intensity measurements 
were made whilst the BGL was changing; 
the measured BGL values varied from 
about 80 to 220 mg/dl in all of the subjects. 
The beat-by-beat spectral data of blood 
( λOD∆ ) against a measured BGL were calcu-
lated to obtain an averaged spectral curve of 
λOD∆  obtained from stable and almost similar 
waveforms of the pulsatile intensity changes of 
3-5 consecutive cardiac beats during the meas-
urement interval of 20-30 s. The spectrum of 
λOD∆  was then normalised, using the value of 
the λOD∆  at 900 nm as 1.0 together with the 
minimum value of λOD∆  as 0. Thus 603 
paired data sets of the measured BGL values and 
the normalised spectra of λ  were ob-
tained from the 27 healthy volunteers for use in 
the PLS modelling for which we employed the 
MATLAB
OD∆
TM PLS Toolbox 3.5 (Eigenvector Inc., 
USA). We have used 2/3rds of the data for deriv-
ing the PLS calibration model and the remaining 
1/3rd for prediction. Two methods for selecting 
the data were used: (A) In the first method we 
randomly selected 402 data sets for calibration 
and used the remaining 201 data sets for predic-
tion; (B) In the second method we randomly se-
lected 18 subjects, using all of their data for cali-
bration, leaving the data from the remaining 9 
subjects for prediction. The analysis based on 
method (B) then allowed us to plot the 
time-course of predicted and measured BGL in 
any of the 9 subjects.  
Results 
The optical data collected during each 20-30 s 
measurement period allowed transmittance 
spectra to be plotted and for the temporal changes 
throughout each cardiac cycle to be seen. Fig. 3 
shows an example of a 3-dimensional represen-
tation of the transmitted radiation intensity in 
arbitrary units (a.u.) (Iλ a.u.: vertical axis, y), vs 
wavelength λ (nm, horizontal axis, x) and vs time 
Fig. 3: An example of 3-dimensional display of trans-
mitted radiation intensity ( ), wavelength (λ) and 
time (t) measured in the fingertip. Measuring scene is 
shown in the inset. 
λI
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t (s, horizontal axis, z) measured in the fingertip 
of a female subject. From these transmittance 
spectra it can be seen that the intensity exhibits a 
peak around 1100 nm and it is considerably de-
creased beyond approximately 1200 nm due to 
the strong absorption by the water component in 
the tissue, including blood. Pulsatile intensity 
changes with time, being of cardiac origin, can be 
seen as a ‘ripple’ on the peak intensity at 1100 nm. 
These pulsatile changes are then shown more 
clearly in Fig. 4 for specific wavelengths at 100 
nm intervals from 900 nm to 1700 nm.  
The PLS models were assessed by examination of 
the regression coefficient vectors [9, 10, 15, 18, 28]. 
Presence of positive peaks in the regression co-
efficients was seen in the spectral regions asso-
ciated with glucose absorption indicating that 
these wavelengths have positive correlations to 
the tissue glucose content. 
As mentioned above we used two methods for 
selecting sets of data for model calibration and 
prediction, method (A) 
involving the random 
selection of 402 data sets 
from the total 603 data 
sets and method (B) in 
which we randomly se-
lected 18 subjects, using 
all of their data for cali-
bration and the data from 
the remaining 9 subjects 
for prediction. Method 
(B) allows the 
time-course of measured 
and predicted BGL lev-
els to be plotted for each 
individual subject and a 
typical example of such a 
time-course of measured 
BGL levels (Fuji 
DRI-CHEM) before and 
after administration of 
glucose solution is 
shown in Fig. 5 (a).  Using the pulsatile intensity 
measurements as shown in Fig. 4 the corre-
sponding optical density changes, λ , were 
calculated for the whole spectral range and were 
then averaged for the measured cardiac beats to 
OD∆
Fig. 4: Examples of pulsatile component ( λI∆ ) records superimposed on 
the transmitted radiation intensity ( ) measured from λ = 900 to λ = 
1700 nm every 100 nm step obtained in the fingertip of the same subject 
in Fig 3. 
λI
Fig. 5: (a) An example of the time course of the 
measured and predicted BGL values before and after 
oral administration of glucose solution indicated by the 
arrow, (b) averaged spectrum of optical density 
( ) obtained from 4 consecutive cardiac beats at 
a point (I) in (a) calculated from the light intensities (  
and ), and (c) 
λOD∆
λI
λI∆ λOD∆  spectra which was nor-
malised using the value of the  at 900 nm as 
1.0 together with the minimum value of 
λOD∆
λOD∆  as 0 in 
each calculated spectrum obtained at the points (I), (II), 
(III) and (IV) in (a). The time course was obtained from 
the analysis based on method (B). 
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obtain a spectral curve of ∆ODλ: Standard de-
viations of the averaged λ  spectral 
curves were within 1 % between 900 and 1300 
nm and were within about 2 % beyond 1300 nm 
for the various BGL levels in the present glucose 
tolerance tests. An example of the averaged 
λ  obtained from 4 consecutive cardiac 
beats is shown in Fig. 5(b), which corresponds to 
time point ‘I’ in Fig. 5(a). This procedure was 
repeated for all of the data collected during the 
glucose tolerance test, and the resulting spectra 
corresponding to the BGL values at time points 
‘I’, ‘II’, ‘III’ and ‘IV’, are normalized and are 
shown in Fig. 5(c). Predicted values of BGL were 
subsequently calculated using the PLS model and 
are also plotted in Fig. 5(a) together with the 
blood analysis results.  
OD∆
OD∆
For both method (A) and method (B) the paired 
data sets of the measured (Fuji DRI-CHEM) and 
predicted (Pulse Glucometry) BGL values were 
[29]
also using error-grid analysis 
analysed by the Bland-Altman method  and 
r-grid for the results of method (A) is 
oth methods of 
Discussion  
ent of a reliable and convenient 
[ ]30 . The result of the 
Bland-Altman analysis for 201 paired data from 
method (A), corresponding to a range in meas-
ured BGL values from 93 to 216 mg/dl, is shown 
in Fig. 6. The bias and precision of the predic-
tions obtained by Pulse Glucometry as compared 
with direct blood analysis averaged 1.22±22.3 
(mean ± SD) mg/dl. Using method (B), with 129 
paired data corresponding to a range in measured 
BGL values from 93 to 211 mg/dl, we found a 
bias and precision of -2.48±21.9 (mean ± SD) 
mg/dl.  
The erro
shown in Fig. 7. This indicates that 181 data pairs 
(90.05 %) fell within region A, and 20 data pairs 
(9.95%) fell within region B. The error-grid 
analysis for method (B) showed that 119 data 
pairs (92.2%) fell within range A and 10 data 
pairs (7.8%) fell within range B. 
These results indicate that, for b
analysis (A and B) the new method, Pulse Glu-
cometry, was able to produce BGL estimates with 
precision and accuracy suitable for clinical pur-
poses.  
The developm
non-invasive method for blood glucose (BGL) 
monitoring in order to avoid the need for blood 
sampling has been the focus of intense efforts for 
several decades [1, 3]. Among the possible 
non-invasive approaches those based on optical 
methods have seemed attractive but to date there 
has been no report of an entirely successful in-
strument [ ]31 . In vivo spectrophotometric analysis 
is confounded by a number of factors, especially 
the influences of absorption and scatter by nu-
merous tissue components, such as water, bone, 
muscle, skin and the very many chemical con-
stituents in blood other than glucose [17]. The 
strong absorption bands of water make the spe-
cific extraction of glucose absorption data tech-
nically difficult. Our approach is to utilise a 
change in the blood volume of an interrogated 
tissue segment, such as a fingertip, produced by 
the cardiac-related pulse in order to eliminate the 
basal interfering components. This approach may 
be compared with the widely used method of 
pulse oximetry which uses two specific wave-
lengths for oxygen saturation monitoring [ ] 32 . In 
this connection Heise et al [15] suggested the pos-
sible use of diffuse reflectance spectroscopy for 
glucose measurement on human oral mucosa and 
that pulsatile absorbance spectral measurement 
might be further investigated. These authors were 
unable to measure pulsatile spectra on the lip, 
Fig. 6: Difference between predicted and 
measured BGL values plotted against their 
average (Bland-Altman plot) analysed by 
method (A). See text for further explanation. 
Fig. 7: A scatter diagram showing comparison 
of the predicted and measured BGL values by 
error-grid analysis obtained by method (A). 
Values in regions A and B are acceptable for 
clinical use. See text for explanation. 
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there apparently being problems of the spectral 
SNR as well as inadequate time resolution of 
their instrumentation.  
We have used venous blood samples for the 
We have designed and constructed a spectro-
pect to the matter of water absorption 
construction of our PLS model, since venous 
blood sampling is used clinically and arterial 
blood sampling was felt not to be justified in 
healthy volunteers. We have noted optical inten-
sity changes reflecting venous blood volume 
changes with breathing. It is theoretically possi-
ble to use these intensity changes to calculate 
BGL levels, but the signals are not as clear and 
reliable as the arterial blood volume pulsations. It 
is known that arterial BGL values may be 
10-20% higher, or more, than venous BGL values 
[ ]33 . 
photometric measurement system which is capa-
ble of deriving transmittance spectra from an 
adult human finger at sufficiently high speed to 
reveal cardiac-related pulsatile spectra over the 
near infra-red spectrum from 900 nm to 1700 nm. 
Reported in vitro absorption spectra of whole 
blood exhibit a large peak at around 1450 nm due 
to water. Interestingly, we found that the in vivo 
spectrum of the pulsatile blood compartment, as 
shown in Fig. 5(b) and 5(c), is consistently 
markedly different to the in vitro spectrum, es-
pecially in the wavelength range beyond 1300 nm. 
The reasons for this are at present unclear. 
However, in their paper on time-resolved 
near-infrared spectroscopy Nahm and Gehring 
[22] reported so-called “static” and pulsatile parts 
of finger tip optical density over the wavelength 
range from 600 nm to 1012 nm (16,667 cm-1 to 
9880 cm-1). The “static” spectrum reveals the 
known water absorption band around 966 nm, 
with a magnitude of approximately 0.6 ODU (or 
AU). However, the water absorption band is 
missing in the spectrum derived from pulsatile 
signals, which only reveals a part of the haemo-
globin spectrum appearing between 643 nm and 
602 nm. These authors do not give a detailed 
explanation for this finding, merely stating that it 
can be explained by a strong influence of ex-
tra-vascular water on the static spectrum, but no 
estimates for the relative proportions of the in-
tra-vascular and extra-vascular compartments in 
the fingertip are given. These authors use a 
multi-layer model of tissue comprising of 
bloodless tissue, intra-venous space and in-
tra-arterial space. This model assumes, firstly, 
that scattering effects are ignored and, secondly, 
that changes in optical density due to car-
diac-related pulsatile blood volume are created 
by changes in the pathlength of the intra-arterial 
space. Although it is not clear from the descrip-
tion of their experimental arrangement we as-
sume that the positioning of their optical fibres 
for the incident and transmitted radiation is such 
that the finger is free to change diameter during 
the pulsatile changes in volume/pathlength. By 
contrast with their arrangement we specifically 
ensure that our optical fibres are fixed in gentle 
contact with the opposing surfaces of the finger 
such that the intra-fibre distance, and therefore 
the finger diameter, cannot change during the 
arterial pulse. In this case any changes in in-
tra-arterial volume must be compensated for by 
opposite changes in intra-venous space. A simple 
analysis of this situation, bearing in mind that we 
derive difference spectra, suggests that this may 
lead to subtraction of the water spectrum. The 
obvious limitation of this simple analysis is that it 
does not fully account for changes in attenuation 
across the finger caused by scattering phenomena 
and we will study this further in our on-going 
research, but we now discuss scattering aspects 
further. 
With res
bands and to the critical issues of selectivity and 
choice of spectral range it is inevitable that scat-
tering phenomena play an important role. Am-
erov et al [28] show in their in vitro studies of 
blood that the influence of glucose concentration 
on scattering is the dominant factor in what they 
refer to as the short-wavelength region. Their 
work elegantly shows that, in vitro, the most 
important mechanism is that of the influence of 
glucose uptake by blood cells on refractive index. 
In defining the three spectral ranges for their 
studies they do not make a clear distinction be-
tween the first-overtone range and the 
short-wavelength range, simply stating that both 
are included in the range spanning from 9000 
cm-1 to 5400 cm-1 (1.11 µm to 1.851 µm). They 
do, nevertheless, demonstrate much greater sta-
tistical variation in the glucose concentration 
correlation plot when using a PLS calibration 
model with spectral information restricted to the 
narrow spectral region from 8500 cm-1 to 7300 
cm-1 (1.176 µm to 1.369 µm). The measurements 
reported in our present paper, which were of 
course in vivo whole tissue not merely in vitro 
blood samples, were actually made over the range 
of 11,111 cm-1 to 5882 cm-1 (900 nm to 1700 nm). 
We therefore include both the first-overtone 
range and the restricted short-wavelength range 
used by Amerov et al. It is not clear at this stage 
what effect this has on the performance of our 
instrument for blood glucose predictions and the 
implications of this will be fully investigated in 
our future research. Suffice it to say that we be-
lieve that the influences of scatter are much more 
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complex in the in vivo situation as compared with 
the in vitro model. 
The choice of spectral range is important for two 
reasons; firstly, it obviously influences the ability 
to recognise the target molecule from its known 
absorption bands amidst other absorbing species; 
secondly, it requires consideration of the likely 
wavelength-dependent effects of scattering phe-
nomena that have a profound influence on optical 
pathlength. The matter of optical pathlength is 
critical in any attempt to derive quantitative 
measurements using spectrophotometry and this 
is especially important for in vivo determinations. 
Multiple scatter by tissues is a well-known and 
extensively studied phenomenon and many 
groups have made measurements of effective 
optical pathlength [17]. Actual optical pathlength 
estimates in some tissues can be made, with 
varying degrees of precision and accuracy, by 
using what has been defined as the optical path-
length factor, ζ , which is given by the relation-
ship Lo = ζ  L here L, w o is the optical pathlength 
and L is th hysical pathlength e p [17]. Some authors 
refer to this as the differential pathlength factor, 
or DPF. Measurements of ζ  have been made in 
various tissues and, for example, human brain has ζ  ranging from 4 to 5. ζ  for the adult fingertip 
of a similar magnitud so that if the physical 
pathlength of the fingertip is 10 mm the optical 
pathlength could be as much as 50 mm. This 
clearly has a significant impact on quantitative 
estimates using spectrophotometric methods. 




ity of PLS models and 
ol we used glucose 
frequency domain measurements to measure the 
reduced scattering coefficient of various tissues 
(vascular and avascular), have reported wave-
length-dependence following classical Mie the-
ory [ , ] 34 35 . Recent studies in the human fingertip 
over the range 850 nm to 1050 nm actually show 
clearly the expected linear fall in reduced scat-
tering coefficient with increasing wavelength [ ]36 . 
Propagation of radiation through tissues is thus, 
naturally, influenced by wavelength, but is also 
influenced by the positioning of interrogating 
fibres and by applied pressure [ ]37 . In diffuse re-
flectance measurements, which are now popular 
for blood glucose determinations, the penetration 
depth and therefore the interrogated volume are 
related to the geometrical spacing between 
transmitting and receiving fibres [10]. 
In common with many others using 
either non-invasive chemical measurement or in 
vitro analysis we have used the multivariate sta-
tistical method of PLS regression. Although this 
method has the potential to provide meaningful 
predictions great care is needed since it has been 
suggested that chance correlations can produce 
highly misleading results [14, 15, 18, 31]. It has also 
been shown that use of time-correlated data as in 
conventional glucose tolerance tests can lead to 
false claims of model functionality [ ]38 . Using a 
phantom containing fat and aqueous protein so-
lutions to simulate human spectra, but in the ab-
sence of glucose, these authors showed that if 
typical glucose tolerance test time profiles were 
used in assigning glucose concentrations to 
spectra within their phantom glucose data set, the 
PLS calibration models assessed with 
leave-one-out cross validation performed well; 
this is a very disturbing finding. In addition they 
found that models developed with the 
leave-one-out cross validation method were 
similar to those based on the use of an inde-
pendent prediction set. 
In order to establish valid
their performance in specifically predicting glu-
cose levels some authors employ an examination 
of the regression coefficient vector [10]. We ex-
amined the vector and, using 5 latent variables, 
found generally narrow positive peaks at wave-
lengths characteristic of glucose absorption. For 
example, there was a positive peak around 1000 
nm which is weakly associated with glucose and 
there was a further positive peak around 1620 
nm which is strongly associated with glucose. 
The presence of these positive peaks at these 
wavelengths indicates that they have positive 
correlations with glucose. 
In our experimental protoc
tolerance tests in order to change BGL levels. We 
then employed two methods for analysing the 
collected 603 data sets. In method (A) we ran-
domly selected 402 data sets for calibration and 
used the remaining 201 data sets for prediction. In 
method (B) we randomly selected 18 subjects, 
using all of their data for calibration and leaving 
the data from the remaining 9 subjects for pre-
diction. The reasoning behind this was that ran-
dom selection from the total data set, as in the 
method (A), should reduce the possibility that the 
outcome of the analysis would be influenced by 
the time-correlated changes of blood glucose 
produced during the glucose tolerance test pre-
sent in the data from an individual subject. By 
contrast, the outcome of the analysis based on the 
method (B), where all of the data from each of the 
randomly selected 18 individual subjects were 
included, has the potential to be influenced by the 
time-correlated BGL changes. The results as 
analysed using both the Bland-Altman method 
and the Clark error-grid were, however, very 
similar for the two methods, (A) and (B). This 
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suggests that the time-correlated changes in BGL 
do not, in fact, have an influence on the analysis. 
This first study has been to present the new 
method of Pulse Glucometry for the non-invasive 
BGL measurement along with the design of an 
accurate and high-speed spectrophotometer sys-
tem, and to evaluate the feasibility of this method 
using the limited spectral data sets with a multi-
variate calibration analysis. There is still much to 
be done to evaluate fully all aspects of this 
method. 
The present instrumentation is laboratory-based 
and further development is required to investigate 
the feasibility of designing a small portable de-
vice suitable for patient use to achieve 
self-monitoring. It is also possible that the 
method could provide the possibility for 
non-invasive blood analysis of such substrates as 
triglyceride, albumin, cholesterol, glycated al-
bumin, and so on. Further comprehensive studies 
will need to be carried out in order to investigate 
such possibilities. 
Conclusions 
We have described a new optical method, Pulse 
Glucometry, for non-invasive determination of 
blood glucose levels. A high-speed optical in-
strument has been successfully developed for 
gathering transmittance spectra from the adult 
human finger over the wavelength range of 900 to 
1700nm. We have been able to determine car-
diac-related pulsatile changes in optical density 
and, using a PLS calibration model for glucose, 
we have subsequently been able to derive blood 
glucose estimates non-invasively in twenty-seven 
healthy adult subjects during glucose tolerance 
tests. The results indicate that the technique can 
produce blood glucose estimates with acceptable 
precision and accuracy for clinical use. Since the 
present study is a first stage to validate the new 
method, further work is required to determine 
fully the performance of the instrument in dia-
betic subjects and also to assess the full potential 
of this method for clinical and research purposes. 
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